Clinical Trial: Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio(R) in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06941025) titled 'Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio(R) in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding' on April 16.

Brief Summary: The goal of this observational registry is to evaluate the safety and outcomes of pregnancy and lactation in women with Fabry disease who are exposed to pegunigalsidase alfa within 30 days prior to conception and/or during pregnancy and lactation.

The main objectives are to:

* Assess pregnancy outcomes, including maternal and infant health.

* Evaluate the occurrence of congenital malformations and other neonat...